Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Cash from Investing Activities (2016 - 2025)

Corcept Therapeutics' Cash from Investing Activities history spans 10 years, with the latest figure at -$11.8 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 81.6% year-over-year to -$11.8 million; the TTM value through Dec 2025 reached $69.8 million, up 139.28%, while the annual FY2025 figure was $69.8 million, 139.28% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$11.8 million at Corcept Therapeutics, down from $14.6 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $207.5 million in Q1 2023 and bottomed at -$109.6 million in Q3 2023.
  • The 5-year median for Cash from Investing Activities is -$10.4 million (2024), against an average of $242950.0.
  • The largest annual shift saw Cash from Investing Activities surged 1151.97% in 2021 before it crashed 2187.47% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at $140.5 million in 2021, then crashed by 112.27% to -$17.2 million in 2022, then soared by 199.17% to $17.1 million in 2023, then crashed by 476.42% to -$64.4 million in 2024, then surged by 81.6% to -$11.8 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Cash from Investing Activities are -$11.8 million (Q4 2025), $14.6 million (Q3 2025), and $70.1 million (Q2 2025).